Cimzia and Chondrocalcinosis - a phase IV clinical study of FDA data

Summary:

Chondrocalcinosis is reported as a side effect among people who take Cimzia (certolizumab pegol), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Methotrexate, and have Psoriasis.

The phase IV clinical study analyzes which people have Chondrocalcinosis when taking Cimzia. It is created by eHealthMe based on reports of 106,367 people who have side effects when taking Cimzia from the FDA, and is updated regularly.

What is Cimzia?

Cimzia has active ingredients of certolizumab pegol. It is often used in rheumatoid arthritis. eHealthMe is studying from 106,745 Cimzia users. Check the latest studies of Cimzia.

What is Chondrocalcinosis?

Chondrocalcinosis (crystal deposition disease) is found to be associated with 164 drugs and 193 conditions by eHealthMe. Check the latest studies of Chondrocalcinosis.

On Jul, 18, 2026

106,367 people reported to have side effects when taking Cimzia.
Among them, 15 people (0.01%) have Chondrocalcinosis.

Among these 15 people:

How long have people been on Cimzia when they have Chondrocalcinosis? *

What is the gender of people who have Chondrocalcinosis when taking Cimzia? *

female: 100 %
male: 0.0 %

What is the age of people who have Chondrocalcinosis when taking Cimzia? *

What are other drugs people take besides Cimzia? *

What are other side effects people have besides Chondrocalcinosis? *

Type Iv Hypersensitivity Reaction (delayed type hypersensitivity as the reaction takes two to three days to develop): 9 people, 60.00%
Drug Intolerance (drug sensitivity): 9 people, 60.00%
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 9 people, 60.00%
Indigestion: 9 people, 60.00%
Spondyloarthropathy (any joint disease of the vertebral column): 9 people, 60.00%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 9 people, 60.00%
Joint Injury: 9 people, 60.00%
Joint Pain: 9 people, 60.00%
Mobility Decreased (ability to move is reduced): 9 people, 60.00%
Gastrointestinal Perforation (hole in the digestive tract): 9 people, 60.00%

What are the existing conditions these people have? *

Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 6.67%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Cimzia and have Chondrocalcinosis?

- Check whether Chondrocalcinosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cimzia:

Cimzia (106,745 reports)

Browse all side effects of Cimzia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chondrocalcinosis:

Chondrocalcinosis (164 drugs)

Browse all the conditions that are associated with Chondrocalcinosis:

Chondrocalcinosis (193 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on certolizumab pegol (the active ingredients of Cimzia) and Cimzia (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.